Immix Biopharma (IMMX) Receivables (2024 - 2026)

Immix Biopharma has disclosed Receivables across 3 years of filings, most recently posting $6.2 million for Q1 2026.

• Receivables for Q1 2026 came in at $6.2 million, up 264.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.2 million (up 264.71% YoY), and the FY2025 annual result was $4.6 million, up 142.11% from the prior year.
• Receivables came in at $6.2 million for Q1 2026 at Immix Biopharma, up from $4.6 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $6.2 million in Q1 2026 to a low of $1.7 million in Q1 2025.
• The 3-year median for Receivables is $4.1 million (2025), against an average of $3.8 million.
• Across the five-year window, Receivables soared 142.11% in 2025 and jumped 264.71% in 2026, its largest moves.
• Immix Biopharma's Receivables stood at $1.9 million in 2024, then jumped by 142.11% to $4.6 million in 2025, then soared by 34.78% to $6.2 million in 2026.
• The last three Receivables figures came in at $6.2 million (Q1 2026), $4.6 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.